Kraivichian Kanyarat, Nuchprayoon Surang, Sitichalernchai Prasert, Chaicumpa Wanpen, Yentakam Sutin
Department of Parasitology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Am J Trop Med Hyg. 2004 Nov;71(5):623-8.
In a randomized open study, we compared the efficacy of a single dose of oral ivermectin (200 microg/kg) and oral albendazole (400 mg/day for 21 days) for the treatment of cutaneous gnathostomiasis. Thirty-one patients were randomly assigned to receive ivermectin (n = 17) or albendazole (n = 14). Thirteen of 17 patients who received ivermectin responded, 3 relapsed, and 1 was unresponsive (cure rate = 76%). Thirteen of 14 patients who received albendazole responded very well and did not relapse. Only one patient was unresponsive (cure rate = 92%; P > 0.05). No major side effects were observed in both groups. We concluded that a single dose of ivermectin (200 microg/kg) is less effective than albendazole (400 mg/day for 21 days) for treatment of cutaneous gnathostomiasis, but there was no statistically significant difference (P > 0.05).
在一项随机开放研究中，我们比较了单剂量口服伊维菌素（200微克/千克）和口服阿苯达唑（400毫克/天，共21天）治疗皮肤颚口线虫病的疗效。31例患者被随机分配接受伊维菌素治疗（n = 17）或阿苯达唑治疗（n = 14）。接受伊维菌素治疗的17例患者中，13例有反应，3例复发，1例无反应（治愈率 = 76%）。接受阿苯达唑治疗的14例患者中，13例反应良好且未复发。只有1例患者无反应（治愈率 = 92%；P>0.05）。两组均未观察到严重副作用。我们得出结论，单剂量伊维菌素（200微克/千克）治疗皮肤颚口线虫病的效果不如阿苯达唑（400毫克/天，共21天），但差异无统计学意义（P>0.05）。
